AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2023
Jan 11, 2023
31523_dirs_2023-01-11_4a53f5d0-eb81-4850-973f-f1ab4e0e59b7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2023-01-09
Reporting Person: Crowley John F (Director, Executive Chairman)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-01-09 | Common Stock | S | 85102 | $11.4328 | Disposed | 885229 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 64895 | Indirect |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $11.24 to $11.74 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.